Roche AG established a firm lead in its effort to deliver the first approved therapy for primary progressive multiple sclerosis (MS), reporting on Monday that its CD20-targeted MAb, ocrelizumab, helped patients achieve a sustained and significant reduction in clinical disability vs. placebo over 12 weeks.